Cartesian Therapeutics Financials - Benzinga

Cartesian Therapeutics Inc

RNACNASDAQ

Trade with Public

Trade with Public

$10.23

-0.26-2.48%

At close: Aug 19, 5:00 PM EST

$10.11

-0.38-3.62%

Pre-Market: 8:05 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Cartesian Therapeutics Financials

Cartesian Therapeutics (RNAC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $(0.86) by 153.49 percent. This is a 8 percent decrease over earnings of $0.50 per share

Benzinga Newsdesk

PRO
Cartesian Therapeutics Q1 EPS $(1.46) Misses $(0.88) Estimate, Sales $78.000K Miss $99.833K Estimate

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.88) by 65.91 percent. This is a 114.71 percent decrease over losses of $(0.68) per

Benzinga Newsdesk

PRO
CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat $94.67K Estimate. Adj. EPS excludes Impairment Charges Of $56.7M

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.85) by 62.95 percent. This is a 247.5 percent decrease over losses of $(0.40) per

Benzinga Newsdesk

Insights into Cartesian Therapeutics Q4 Earnings

Benzinga Insights

PRO
Cartesian Therapeutics Q3 EPS $(1.38) Misses $(0.84) Estimate, Sales $452.000K Beat $243.500K Estimate

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(0.84) by 63.31 percent. This is a 22.12 percent decrease over losses of $(1.13) per

Benzinga Newsdesk

PRO
Cartesian Therapeutics Q2 EPS $0.50 Compared With $0.54 YoY, Sales Total $298.000K

Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.82) by 160.98 percent. This is a 7.41 percent decrease over earnings of $0.54 per share

Benzinga Newsdesk